The estimated Net Worth of Robert A Beardsley is at least $1.68 Million dollars as of 21 November 2022. Robert Beardsley owns over 10,000 units of Galera Therapeutics Inc stock worth over $7,898 and over the last 5 years he sold GRTX stock worth over $0. In addition, he makes $1,668,210 as Chief Operating Officer at Galera Therapeutics Inc.
Sign up
Robert Beardsley GRTX stock SEC Form 4 insiders trading
Robert has made over 3 trades of the Galera Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of GRTX stock worth $10,700 on 21 November 2022.
The largest trade he's ever made was exercising 20,000 units of Galera Therapeutics Inc stock on 17 December 2021 worth over $21,400. On average, Robert trades about 5,000 units every 42 days since 2019. As of 21 November 2022 he still owns at least 108,191 units of Galera Therapeutics Inc stock.
You can see the complete history of Robert Beardsley stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Beardsley biography
Dr. Robert A. Beardsley Ph.D. serves as Chief Operating Officer of the Company. He is a co-founder of the Company, has served as our Chief Operating Officer since 2015, and from 2012 to 2017 as our Executive Chair. Prior to this, Dr. Beardsley was the Chief Executive Officer at Galera Therapeutics, LLC from 2010 to 2012, at Metabolic Solutions Development Corporation from 2009 until 2010, and at Kereos from 2003 until 2009, and the acting Chief Executive Officer at Metaphore Pharmaceuticals, Inc. in 2002. He has also served in various management roles at Confluence Life Sciences, bioStrategies Group, Vector Securities International, Enzyme Organics and Mobil Oil. Dr. Beardsley has served on a number of public and private boards including Euclises, Epigenetx, KemPharm, Kereos, CollaGenex Pharmaceuticals, Bioseek, and Metaphore Pharmaceuticals. Dr. Beardsley received a B.S. in Chemical Engineering, a Ph.D. in Biochemical Engineering from the University of Iowa and an M.B.A. in Finance from the University of Chicago.
What is the salary of Robert Beardsley?
As the Chief Operating Officer of Galera Therapeutics Inc, the total compensation of Robert Beardsley at Galera Therapeutics Inc is $1,668,210. There are 2 executives at Galera Therapeutics Inc getting paid more, with J. Mel Sorensen having the highest compensation of $2,465,100.
How old is Robert Beardsley?
Robert Beardsley is 59, he's been the Chief Operating Officer of Galera Therapeutics Inc since 2015. There are 11 older and 5 younger executives at Galera Therapeutics Inc. The oldest executive at Galera Therapeutics Inc is Joel F. Sussman, 72, who is the Chief Accounting Officer & Treasurer.
What's Robert Beardsley's mailing address?
Robert's mailing address filed with the SEC is C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD #100, MALVERN, PA, 19355.
Insiders trading at Galera Therapeutics Inc
Over the last 5 years, insiders at Galera Therapeutics Inc have traded over $19,201,067 worth of Galera Therapeutics Inc stock and bought 3,540,438 units worth $29,883,202 . The most active insiders traders include Holdings A/S Novo, Group Inc Blackstone Group ... und Bioventures Ltd Novartis Ag.... On average, Galera Therapeutics Inc executives and independent directors trade stock every 47 days with the average trade being worth of $11,809. The most recent stock trade was executed by Mel Sorensen on 16 August 2024, trading 67,015 units of GRTX stock currently worth $4,691.
What does Galera Therapeutics Inc do?
galera therapeutics, inc. is a pharmaceuticals company located in 101 lindenwood dr, malvern, pennsylvania, united states.
What does Galera Therapeutics Inc's logo look like?
Complete history of Robert Beardsley stock trades at Galera Therapeutics Inc
Galera Therapeutics Inc executives and stock owners
Galera Therapeutics Inc executives and other stock owners filed with the SEC include:
-
J. Mel Sorensen,
President, Chief Executive Officer, Director -
Christopher Degnan,
Chief Financial Officer -
Robert Beardsley,
Chief Operating Officer -
Dr. J. Mel Sorensen,
CEO, Pres & Director -
Christopher Degnan,
CFO & Sec. -
Dr. Robert A. Beardsley,
Co-Founder & COO -
Arthur Fratamico,
Chief Business Officer -
Jon Holmlund,
Chief Medical Officer -
Lawrence Alleva,
Independent Director -
Michael Powell,
Independent Chairman of the Board -
Emmett Cunningham,
Director -
Kevin Lokay,
Independent Director -
Linda West,
Independent Director -
Joel Sussman,
Chief Accounting Officer -
Mark J. Bachleda M.B.A., Pharm.D.,
Chief Commercial Officer -
Arthur J. Fratamico,
Chief Bus. Officer -
Dr. Jon T. Holmlund,
Chief Medical Officer -
Jennifer Evans Stacey Esq.,
Chief Legal & Compliance Officer and Sec. -
Dr. Dennis P. Riley Ph.D.,
Chief Scientific Officer -
Joel F. Sussman,
Chief Accounting Officer & Treasurer -
Bioventures Ltd Novartis Ag...,
-
Chris Degnan,
Chief Financial Officer -
Jason Fuller,
Director -
Iv A, L.P.Clarus Iv B, L.P....,
-
Group Inc Blackstone Group ...,
-
Clarus Gp L.P.Blackstone Cl...,
-
Enterprise Associates 14, L...,
-
Venture Partners Ix, L.P.So...,
-
Dennis Riley,
Chief Scientific Officer -
Holdings A/S Novo,
10% owner -
Mark Bachleda,
Chief Commercial Officer -
Jennifer Evans Stacey,
See Remarks -
Yair Schneid,
10% owner -
Eugene P. Kennedy,
Chief Medical Officer -
Mel Sorensen,
President and CEO